LRMR Larimar Therapeutics, Inc.

8-K Current Report

Filed: February 24, 2026

Health Care

Pharmaceutical Preparations

Larimar Therapeutics, Inc. (LRMR) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• FDA granted Breakthrough Therapy Designation (BTD) to nomlabofusp for Friedreich's ataxia treatment in both adults and children
• BTD is a high-value regulatory milestone — accelerates FDA development/review and signals strong clinical evidence of substantial improvement over existing therapies

+2 more insights

Other Larimar Therapeutics, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Mar 9, 2026

8-K Feb 27, 2026

Get deeper insights on Larimar Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.